Blog

WJTV (Jackson): Mississippi Braves Broadcaster Chris Harris Doesn’t Let Rare Eye Disease Hold Him Back

“This surgery…has given me kind of a second chance at being able to do things at a level I never thought I would be able to do.” – Chris Harris, broadcaster for the Mississippi Braves

Interview.

Chris Harris is an accomplished broadcaster for the Mississippi Braves, calling over 1,500 games so far in his career. However, Chris’ livelihood was challenged when he began developing vision loss and piercing headaches on a daily basis.

Worried about his future, Chris searched for answers by visting ENT doctors, psychologists, and brain specialists. When they were unable to give a proper diagnosis, Chris began to wonder if he would ever find the true cause of his recent struggles. Finally, a trip to the eye doctor revealed something unexpected – he was living with keratoconus.

Finally, after being given the diagnosis, Chris was referred to Dr. William Ashford from Eye Surgery and Laser Center, which he called a “new hope”. Dr. Ashford told him about iLink™ FDA-approved cross-linking, which would halt or slow the progression of his keratoconus, and Chris agreed to undergo the procedure one week after baseball season ended. Chris is now able to call games at a level he hasn’t achieved in several years and is advocating for others to “Just do your due diligence. Go to the eye doctor. Get your eyes checked. If you’re experiencing some of the things – headaches, if you’re not sure why your vision has quickly deteriorated, this could be it. There’s help available.”

Chris recently spoke with WJTV Sports Director, Noah Newman, about his journey living with keratoconus, undergoing cross-linking, and his life following the procedure. You can watch the full interview below.

For more information on FDA approved cross-linking, see Prescribing Information and follow Glaukos on Twitter, Facebook, and LinkedIn.

Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink™ corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]

Indications

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epethelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go www.livingwithkeratoconus.com to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Reference

1. Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016